These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25174628)

  • 21. Antiretroviral therapy for prevention of HIV and tuberculosis: a promising intervention but not a panacea.
    McNairy ML; Howard AA; El-Sadr WM
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S200-7. PubMed ID: 23764636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.
    Meyer-Rath G; Over M
    PLoS Med; 2012; 9(7):e1001247. PubMed ID: 22802731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study.
    Knight R; Small W; Thomson K; Gilbert M; Shoveller J
    BMC Public Health; 2016 Mar; 16():262. PubMed ID: 26975718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral adherence interventions in Southern Africa: implications for using HIV treatments for prevention.
    Dewing S; Mathews C; Fatti G; Grimwood A; Boulle A
    Curr HIV/AIDS Rep; 2014 Mar; 11(1):63-71. PubMed ID: 24390683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.
    Forsyth AD; Valdiserri RO
    Curr Opin HIV AIDS; 2012 Mar; 7(2):111-6. PubMed ID: 22227586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels.
    Hoffmann CJ; Gallant JE
    Infect Dis Clin North Am; 2014 Dec; 28(4):549-61. PubMed ID: 25287588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - operations research.
    Kort R
    J Int AIDS Soc; 2010 Jun; 13 Suppl 1(Suppl 1):S5. PubMed ID: 20519026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining HIV programmes for seasonal migrant labourers.
    Kelly SL; Shattock AJ; Kerr CC; Stuart RM; Papoyan A; Grigoryan T; Hovhannisyan R; Grigoryan S; Benedikt C; Wilson DP
    J Int AIDS Soc; 2016; 19(1):20772. PubMed ID: 27281790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
    Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
    Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
    Zhang L; Phanuphak N; Henderson K; Nonenoy S; Srikaew S; Shattock AJ; Kerr CC; Omune B; van Griensven F; Osornprasop S; Oelrichs R; Ananworanich J; Wilson DP
    Lancet HIV; 2015 May; 2(5):e200-7. PubMed ID: 26423002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial.
    Walsh FJ; Bärnighausen T; Delva W; Fleming Y; Khumalo G; Lejeune CL; Mazibuko S; Mlambo CK; Reis R; Spiegelman D; Zwane M; Okello V
    Trials; 2017 Aug; 18(1):383. PubMed ID: 28821264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV treatment and care in resource-constrained environments: challenges for the next decade.
    Eholié SP; Aoussi FE; Ouattara IS; Bissagnéné E; Anglaret X
    J Int AIDS Soc; 2012 Aug; 15(2):17334. PubMed ID: 22944479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach.
    Zakumumpa H; Bennett S; Ssengooba F
    BMC Health Serv Res; 2017 Jan; 17(1):65. PubMed ID: 28114932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.
    Barker C; Dutta A; Klein K
    J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21648. PubMed ID: 28770597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam.
    Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Reyes J; Doran C; Zhang L
    AIDS Patient Care STDS; 2014 Jul; 28(7):365-71. PubMed ID: 24983389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term costs and health impact of continued global fund support for antiretroviral therapy.
    Stover J; Korenromp EL; Blakley M; Komatsu R; Viisainen K; Bollinger L; Atun R
    PLoS One; 2011; 6(6):e21048. PubMed ID: 21731646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What do the implementation outcome variables tell us about the scaling-up of the antiretroviral treatment adherence clubs in South Africa? A document review.
    Mukumbang FC; Orth Z; van Wyk B
    Health Res Policy Syst; 2019 Mar; 17(1):28. PubMed ID: 30871565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study.
    Herce ME; Hoffmann CJ; Fielding K; Topp SM; Hausler H; Chimoyi L; Smith HJ; Chetty-Makkan CM; Mukora R; Tlali M; Olivier AJ; Muyoyeta M; Reid SE; Charalambous S
    Lancet HIV; 2020 Dec; 7(12):e807-e816. PubMed ID: 32763152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.